<DOC>
	<DOCNO>NCT02283424</DOCNO>
	<brief_summary>This randomize , open , prospective control trial clinical effectiveness Icotinib adjunctive treatment surgery stage I-IIIB lung adenocarcinoma patient epidermal growth factor receptor gene mutation</brief_summary>
	<brief_title>Icotinib Adjunctive Treatment After Surgery Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation</brief_title>
	<detailed_description>In trial investigator enlist 100 patient accept surgery epidermal growth factor receptor gene mutation , patient divide 2 group ( chemotherapy group Icotinib group ) , compare PFS , RFS , OS 5 year follow</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1875 year old Lung adenocarcinoma patient epidermal growth factor receptor gene mutation , stage IIIIB surgery The patient ' Eastern Cooperative Oncology Group score â‰¤ 02 Mismatch condition Have use anticancer therapy drug trial may influence outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>